793 Targeting engineered interleukin-2 (IL-2) to antigen specific T cells via novel biologic platforms

• Ronald Seidel,
• Natasha Girgis,
• Zohra Merazga,
• Anish Suri,
• John Ross,
• Raymond Moniz,
• Steve Quayle,
• Ahmet Vakkasoglu,
• Tina Daigneault,
• Simon Low

Affiliations

Ronald Seidel

5Cue Biopharma, Cambridge, MA, USA

Natasha Girgis

1CUE Biopharma, Cambridge, MA, USA

Zohra Merazga

1CUE Biopharma, Cambridge, MA, USA

Anish Suri

1CUE Biopharma, Cambridge, MA, USA

John Ross

Emergency Department, Northwick Park Hospital, London North West University Healthcare NHS Trust, Harrow, UK

Raymond Moniz

15Cue Biopharma Inc, Cambridge, MA, USA

Steve Quayle

15Cue Biopharma Inc, Cambridge, MA, USA

Ahmet Vakkasoglu

Cue BioPharma, Cambridge, MA, United States

Tina Daigneault

Cue BioPharma, Cambridge, MA, United States

Simon Low

Cue BioPharma, Cambridge, MA, United States